Edesa Biotech Inc EDSA

$2.14 +0.01 (0.47%)

Valuation

Market cap
20,632,000
Revenue TTM
$0
Net income TTM
$-7,190,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
37,700
Avg volume
42,858
Day's range
$2.01 – $2.20
Shares out
9,641,000
Stochastic %K
15%
Beta
1.26
Analysts
Strong Buy
Price target
$16.33

Price

Company profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflam...

Show more

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
289 800 9600
Website
https://www.edesabiotech.com
Address
100 Spy Court, Markham, Canada

Latest news

Stocktwits

Rafael_ Nov 9, 3:39 PM
$EDSA Milestone payment=Bad check 12M won't save this company
0 replies
Queenalerts Nov 9, 3:38 PM
$EDSA $OMH OMH 60.50 next resistance, 56.94 halt up
0 replies
cjstocksup Nov 9, 3:37 PM
$EDSA Real milestone payments in the 2 post thread below. This morning the pump ply is running, we have real news, should break the HOD from this AM this afternoon IMO. Most will stop chasing trash plays by then IMO:
0 replies
RaftingMakesHerWET Nov 9, 3:32 PM
$EDSA feels like trash after that dump, dilution or naked shorting... holding but not adding
0 replies
Sid3k Nov 9, 3:31 PM
$EDSA best time to enter before noon.
0 replies
RaftingMakesHerWET Nov 9, 3:28 PM
$EDSA a dollar drop on a stock under 5 is needed?
0 replies
Nacho1w Nov 9, 3:26 PM
$EDSA
0 replies
JZen_ Nov 9, 3:23 PM
$EDSA might grab some more down here around $2.70–$2.80. Kyorin deal and the amount of volume coming in today. Took a pretty hard pullback from the highs, but I'm looking for another bounce PT 3.5-5+
0 replies